Pimavanserin Tartrate Patent Expiration
Pimavanserin Tartrate is used for treating symptoms of neurodegenerative diseases such as Parkinson's psychosis and hallucinations. It was first introduced by Acadia Pharmaceuticals Inc
Pimavanserin Tartrate Patents
Given below is the list of patents protecting Pimavanserin Tartrate, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Nuplazid |
US10449185 (Pediatric) | Formulations Of Pimavanserin | Feb 27, 2039 | Acadia Pharms Inc |
| Nuplazid |
US10646480 (Pediatric) | Formulations Of Pimavanserin | Feb 27, 2039 | Acadia Pharms Inc |
| Nuplazid |
US10849891 (Pediatric) | Formulations Of Pimavanserin | Feb 27, 2039 | Acadia Pharms Inc |
| Nuplazid |
US11452721 (Pediatric) | Formulations Of Pimavanserin | Feb 27, 2039 | Acadia Pharms Inc |
| Nuplazid | US10449185 | Formulations of pimavanserin | Aug 27, 2038 | Acadia Pharms Inc |
| Nuplazid | US10646480 | Formulations of pimavanserin | Aug 27, 2038 | Acadia Pharms Inc |
| Nuplazid | US10849891 | Formulations of pimavanserin | Aug 27, 2038 | Acadia Pharms Inc |
| Nuplazid | US11452721 | Formulations of pimavanserin | Aug 27, 2038 | Acadia Pharms Inc |
| Nuplazid |
US10517860 (Pediatric) | Combination Of Pimavanserin And Cytochrome P450 Modulators | Sep 23, 2037 | Acadia Pharms Inc |
| Nuplazid |
US10953000 (Pediatric) | Combination Of Pimavanserin And Cytochrome P450 Modulators | Sep 23, 2037 | Acadia Pharms Inc |
| Nuplazid | US10517860 | Combination of pimavanserin and cytochrome P450 modulators | Mar 23, 2037 | Acadia Pharms Inc |
| Nuplazid | US10953000 | Combination of pimavanserin and cytochrome P450 modulators | Mar 23, 2037 | Acadia Pharms Inc |
| Nuplazid |
US7601740 (Pediatric) | Selective Serotonin 2A/2C Receptor Inverse Agonists As Therapeutics For Neurodegenerative Diseases | Oct 29, 2030 | Acadia Pharms Inc |
| Nuplazid | US7601740 | Selective serotonin 2A/2C receptor inverse agonists as therapeutics for neurodegenerative diseases | Apr 29, 2030 | Acadia Pharms Inc |
| Nuplazid |
US7732615 (Pediatric) | N-(4-Fluorobenzyl)-N-(1-Methylpiperidin-4-Yl)-N′-(4-(2-Methylpropyloxy)Phenylmethyl)Carbamide And Its Tartrate Salt And Crystalline Forms | Dec 03, 2028 | Acadia Pharms Inc |
| Nuplazid | US7732615 | N-(4-fluorobenzyl)-N-(1-methylpiperidin-4-yl)-N′-(4-(2-methylpropyloxy)phenylmethyl)carbamide and its tartrate salt and crystalline forms | Jun 03, 2028 | Acadia Pharms Inc |
| Nuplazid | US7659285 | Selective serotonin 2A/2C receptor inverse agonists as therapeutics for neurodegenerative diseases |
Aug 24, 2026
(Expired) | Acadia Pharms Inc |
| Nuplazid | US7923564 | Synthesis of N-(4-fluorobenzyl)-N-(1-methylpiperidin-4-yl)-N′-(4-(2-methylpropyloxy) phenylmethyl)carbamide and its tartrate salt and crystalline forms |
Sep 26, 2025
(Expired) | Acadia Pharms Inc |
| Nuplazid | US10028944 | Selective serotonin 2A/2C receptor inverse agonists as therapeutics for neurodegenerative diseases |
Jan 15, 2024
(Expired) | Acadia Pharms Inc |
| Nuplazid | US8618130 | Selective serotonin 2A/2C receptor inverse agonists as therapeutics for neurodegenerative diseases |
Jan 15, 2024
(Expired) | Acadia Pharms Inc |
| Nuplazid | US8921393 | Selective serotonin 2A/2C receptor inverse agonists as therapeutics for neurodegenerative diseases |
Jan 15, 2024
(Expired) | Acadia Pharms Inc |
| Nuplazid | US9566271 | Selective serotonin 2A/2C receptor inverse agonists as therapeutics for neurodegenerative diseases |
Jan 15, 2024
(Expired) | Acadia Pharms Inc |
| Nuplazid | US9765053 | Methods of treatment using selective 5-HT2A inverse agonists |
Jul 27, 2022
(Expired) | Acadia Pharms Inc |
| Nuplazid | US7115634 | 4-aminopiperidine and their use as a medicine |
Oct 06, 2021
(Expired) | Acadia Pharms Inc |
| Nuplazid | US6756393 | Azacyclic compounds |
Mar 06, 2021
(Expired) | Acadia Pharms Inc |
| Nuplazid | US6815458 | Azacyclic compounds |
Mar 06, 2021
(Expired) | Acadia Pharms Inc |
| Nuplazid | US9296694 | Azacyclic compounds |
Mar 06, 2021
(Expired) | Acadia Pharms Inc |
| Nuplazid | US7858789 | Derivatives of 4-aminopiperidine and their use as a medicament |
Dec 13, 2020
(Expired) | Acadia Pharms Inc |
| Nuplazid | US8110574 | Derivatives of 4-aminopiperidine and their use as a medicament |
Dec 13, 2020
(Expired) | Acadia Pharms Inc |
Pimavanserin Tartrate's Family Patents
Explore Our Curated Drug Screens
Clinical Trials
Recent Clinical Trials on Pimavanserin Tartrate:
Sometimes companies keep conducting clinical trials even after the drug's approval to discover new formulations, methods of use, or new treatment indications, so they could file for additional patents or receive regulatory exclusivity extensions, such as pediatric exclusivity, potentially delaying generic competition. Based on these recent clinical trials, generic companies need to consider the potential for new intellectual property or regulatory hurdles. These strategic moves by the drug owner might delay generic substitution or lead to additional sales of the brand drug, even after patent expiry.
| Title | Lead Sponsor | Collaborators | Status | Phases |
|---|---|---|---|---|
 | ||||
| Pimavanserin for Rigid-compulsive Symptoms in Autism Spectrum Disorder | New York State Psychiatric Institute | NA |
RECRUITING
(Aug 1, 2026)
| PHASE2 |